BMO upgrades Ionis as Tryngolza adoption picks up in severe hypertriglyceridemia
BMO upgraded Ionis shares as adoption of Tryngolza for severe hypertriglyceridemia grows, according to Seeking Alpha, which reported the analyst move.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at BMO raised their rating on Ionis, pointing to growing use of Tryngolza in patients with severe hypertriglyceridemia. The report was carried by Seeking Alpha.
The source gives no details on a new price target, so the only confirmed point is the rating change itself.
why it matters
An analyst rating change is a routine event, but it shows how the market is judging the pace of uptake for a newer drug. The direct effect mainly concerns Ionis shares and investors in the biotech sector.
tags
instruments
sources
- Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia — Seeking Alpha, 21 October 2026 at 21:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗